Drug intelligence / Profile preview

LNO-401

Development stage: Preclinical
Lead developer: Linno Pharmaceuticals
Modality: Small Molecules
Administration: Transdermal

Overview

LNO-401 is a preclinical-stage transdermal patch candidate being developed by Linno Pharmaceuticals (Lingnuo Pharmaceuticals) for smoking cessation. The product utilizes a transdermal drug delivery system (TDDS) designed to provide sustained release of its active therapeutic agent, aimed at reducing nicotine cravings and withdrawal symptoms. As of early 2024, the program remains in the preclinical phase of development, with the specific active ingredient and molecular target not yet publicly disclosed.

Beyond the preview

Go deeper on LNO-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LNO-401.

Explore the full profile